IN8bio Inc's existing cash of $27.1M as of December 31, 2025, is projected to fund operating expenses and capital expenditure requirements only through April 2027, raising substantial doubt about the company's ability to continue as a going concern.
Bullish
IN8bio Inc's INB-100 trial showed 100% relapse-free survival in AML patients, while INB-200/400 trials demonstrated improved survival in GBM. The company's INB-619 TCE also exhibited strong preclinical efficacy and a favorable safety profile.
Bearish
IN8bio Inc faces substantial doubt as a going concern with limited cash runway, significant clinical development and regulatory uncertainties for its early-stage candidates, and complex manufacturing and supply chain dependencies.